

Jan Henning Klusmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2907464/publications.pdf>

Version: 2024-02-01

105
papers

4,644
citations

126907

33
h-index

106344

65
g-index

129
all docs

129
docs citations

129
times ranked

9307
citing authors

#	ARTICLE	IF	CITATIONS
1	The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. <i>Blood</i> , 2022, 139, 651-665.	1.4	20
2	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. <i>Haematologica</i> , 2022, 107, 759-764.	3.5	3
3	Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 366.e1-366.e7.	1.2	10
4	Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core. <i>Leukemia</i> , 2022, 36, 1926-1930.	7.2	3
5	Long noncoding RNAs as regulators of pediatric acute myeloid leukemia. <i>Molecular and Cellular Pediatrics</i> , 2022, 9, .	1.8	3
6	INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughput <i>in vivo</i> testing. <i>Neuro-Oncology</i> , 2022, 24, i189-i189.	1.2	0
7	Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome. <i>Frontiers in Oncology</i> , 2021, 11, 636633.	2.8	22
8	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	3.7	30
9	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
10	Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS). <i>Klinische Padiatrie</i> , 2021, 233, 267-277.	0.6	4
11	Myeloid Leukemia Dependencies at CTCF-Enriched Long Noncoding RNA Loci. <i>Blood</i> , 2021, 138, 500-500.	1.4	0
12	Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro. <i>Pediatric Research</i> , 2020, 87, 669-676.	2.3	10
13	RNA-Binding Proteins in Acute Leukemias. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3409.	4.1	36
14	Mutations of the gene <i>FNIP1</i> associated with a syndromic autosomal recessive immunodeficiency with cardiomyopathy and pre- ϵ excitation syndrome. <i>European Journal of Immunology</i> , 2020, 50, 1078-1080.	2.9	17
15	YBX1 Indirectly Targets Heterochromatin-Repressed Inflammatory Response-Related Apoptosis Genes through Regulating CBX5 mRNA. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4453.	4.1	11
16	Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation. <i>Leukemia</i> , 2020, 34, 2503-2508.	7.2	4
17	Improved Outcome in Pediatric AML - the AML-BFM 2012 Study. <i>Blood</i> , 2020, 136, 12-14.	1.4	9
18	The long non-coding RNA <i>Cancer Susceptibility 15</i> (<i>CASC15</i>) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e448-453.	3.5	5

#	ARTICLE	IF	CITATIONS
19	The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 570.	2.8	26
20	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. <i>Cancer Cell</i> , 2019, 36, 123-138.e10.	16.8	93
21	2026 - EZH2 LOSS COOPERATES WITH LOSS OF BCOR, TET2 AND RUNX1 DURING LEUKEMOGENESIS AND REACTIVATES A FETAL GENE SIGNATURE. <i>Experimental Hematology</i> , 2019, 76, S48.	0.4	0
22	Molecular Approaches to Treating Pediatric Leukemias. <i>Frontiers in Pediatrics</i> , 2019, 7, 368.	1.9	29
23	The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia. <i>Blood Advances</i> , 2019, 3, 4252-4263.	5.2	22
24	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
25	Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 147-152.	3.4	303
26	Characterization of a Novel JAK1 Pseudokinase Mutation in the First Case of Trisomy 21-Independent GATA1-Mutated Transient Abnormal Myelopoiesis. <i>Blood</i> , 2019, 134, 4208-4208.	1.4	0
27	Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. <i>Leukemia</i> , 2018, 32, 2167-2177.	7.2	155
28	<i>GATA1</i> s exerts developmental stage-specific effects in human hematopoiesis. <i>Haematologica</i> , 2018, 103, e336-e340.	3.5	15
29	Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications. <i>Nucleic Acids Research</i> , 2018, 46, 1375-1385.	14.5	213
30	A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. <i>Leukemia</i> , 2018, 32, 263-272.	7.2	36
31	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1007-1016.	1.6	67
32	Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. <i>Blood Advances</i> , 2018, 2, 1532-1540.	5.2	36
33	Identification of Novel Lncrnas That Predict Survival in AML Patients and Modulate Leukemic Cells. <i>Blood</i> , 2018, 132, 3909-3909.	1.4	2
34	MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2627-2627.	1.4	3
35	Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome. <i>Blood</i> , 2018, 132, 543-543.	1.4	1
36	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. <i>Blood</i> , 2017, 129, 3314-3321.	1.4	64

#	ARTICLE	IF	CITATIONS
37	Reduced <i>Erg</i> Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells. <i>Stem Cells</i> , 2017, 35, 1773-1785.	3.2	16
38	CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells <i>in vivo</i> . <i>Haematologica</i> , 2017, 102, 1558-1566.	3.5	60
39	Deciphering the oncogenic network of PRC2-loss guided leukemogenesis. <i>Experimental Hematology</i> , 2017, 53, S68.	0.4	0
40	lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/ β -catenin signaling. <i>Nature Medicine</i> , 2017, 23, 1331-1341.	30.7	352
41	The non-coding RNA landscape of human hematopoiesis and leukemia. <i>Nature Communications</i> , 2017, 8, 218.	12.8	131
42	The miRNA-193B is a potent tumor-suppressor and a biomarker for poor prognosis in acute myeloid leukemia. <i>Experimental Hematology</i> , 2017, 53, S52.	0.4	0
43	Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells. <i>Blood Advances</i> , 2017, 1, 903-914.	5.2	18
44	Abstract 1895: A conserved E2F1-activated gene regulatory network encompassing monocarboxylic acid transporter-1, its co-operating antisense lncRNA SLC16A1-AS1 and their common downstream targets mediates bladder cancer invasiveness. <i>Cancer Research</i> , 2017, 77, 1895-1895.	0.9	2
45	Classification of pediatric acute myeloid leukemia based on miRNA expression profiles. <i>Oncotarget</i> , 2017, 8, 33078-33085.	1.8	11
46	Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1677-1679.	1.5	18
47	MicroRNA-125b-5p mimic inhibits acute liver failure. <i>Nature Communications</i> , 2016, 7, 11916.	12.8	42
48	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
49	miR-139-5p controls translation in myeloid leukemia through EIF4G2. <i>Oncogene</i> , 2016, 35, 1822-1831.	5.9	51
50	Successes and Challenges of Pediatric AML: A Report on Survival, Salvage Therapy and Causes of Deaths in the AML-BFM Study Group from 1987 -2012. <i>Blood</i> , 2016, 128, 450-450.	1.4	3
51	MicroRNA-106b~25 cluster is upregulated in relapsed <i>MLL</i> -rearranged pediatric acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 48412-48422.	1.8	20
52	The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1534-1534.	1.4	1
53	Lost in translation: pluripotent stem cell-derived hematopoiesis. <i>EMBO Molecular Medicine</i> , 2015, 7, 1388-1402.	6.9	76
54	Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. <i>Annals of Hematology</i> , 2015, 94, 1327-1336.	1.8	54

#	ARTICLE	IF	CITATIONS
55	Crispr-Cas9 Induced MLL-Rearrangements Cause Clonal Outgrowth in CD34+ Hematopoietic Stem Cells. <i>Blood</i> , 2015, 126, 165-165.	1.4	2
56	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1244-1244.	1.4	0
57	Members of the Mir-99/100~125 Tricistrons Cooperatively Induce a Pre-Leukemic Myeloproliferative Disorder. <i>Blood</i> , 2015, 126, 3579-3579.	1.4	0
58	Integrated Analysis of the Human Hematopoietic Non-Coding RNA Landscape Reveals Lnc-RNA Stem Cell Signature in AML. <i>Blood</i> , 2015, 126, 45-45.	1.4	0
59	GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. <i>Leukemia</i> , 2014, 28, 1259-1270.	7.2	36
60	Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. <i>Leukemia</i> , 2014, 28, 577-588.	7.2	112
61	miR-9 is a tumor suppressor in pediatric AML with t(8;21). <i>Leukemia</i> , 2014, 28, 1022-1032.	7.2	72
62	LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. <i>Molecular Cancer</i> , 2014, 13, 171.	19.2	131
63	miR-99a/100b/125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGF β 2 and Wnt signaling. <i>Genes and Development</i> , 2014, 28, 858-874.	5.9	136
64	Microrna-106b~25 Cluster Is Involved in Relapsed MLL-Rearranged Pediatric AML. <i>Blood</i> , 2014, 124, 1038-1038.	1.4	5
65	GATA1-Centered Genetic Network on Chromosome 21 Drives Down Syndrome Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2014, 124, 4310-4310.	1.4	0
66	Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. <i>International Journal of Cancer</i> , 2013, 132, 766-774.	5.1	40
67	Improved Generation of Patient-Specific Induced Pluripotent Stem Cells Using a Chemically-Defined and Matrigel-Based Approach. <i>Current Molecular Medicine</i> , 2013, 13, 765-776.	1.3	9
68	Microrna Expression Profiling In Pediatric Acute Myeloid Leukemia Reveals a Tumor-Suppressive Role Of Mir-9 Associated With Translocation (8;21). <i>Blood</i> , 2013, 122, 1363-1363.	1.4	0
69	Lncrna Hematlas Defines Blood Lineage-Specific RNA Expression Signatures and Novel Lincrna Biomarkers. <i>Blood</i> , 2013, 122, 3669-3669.	1.4	0
70	Characterization Of Oncogenes On Chromosome 21 Identified By shRNA-Based Viability Screening. <i>Blood</i> , 2013, 122, 1201-1201.	1.4	0
71	Prospects and Challenges of Reprogrammed Cells in Hematology and Oncology. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 507-528.	0.8	7
72	Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease. <i>Haematologica</i> , 2012, 97, 632-634.	3.5	3

#	ARTICLE	IF	CITATIONS
73	The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. <i>Haematologica</i> , 2012, 97, 551-559.	3.5	87
74	High frequency of copy number alterations in myeloid leukaemia of Down syndrome. <i>British Journal of Haematology</i> , 2012, 158, 800-803.	2.5	10
75	The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. <i>Haematologica</i> , 2012, 97, 21-29.	3.5	78
76	Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 371-377.	2.1	27
77	miRNAs can increase the efficiency of ex vivo platelet generation. <i>Annals of Hematology</i> , 2012, 91, 1673-1684.	1.8	34
78	Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 689-695.	2.8	114
79	Reduced Erg Dosage Perturbs Fetal and Adult Hematopoiesis. <i>Blood</i> , 2012, 120, 1189-1189.	1.4	0
80	the miR-99/125 Polycistrons Promote Leukemogenesis in a Cell-Context Dependent Manner by Shifting the Balance Between TGF β 2- and Wnt-Signaling. <i>Blood</i> , 2012, 120, 109-109.	1.4	1
81	GATA1s Induces Hyperproliferation of Eosinophil Precursors. <i>Blood</i> , 2012, 120, 2318-2318.	1.4	0
82	Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. <i>Blood</i> , 2011, 118, 2222-2238.	1.4	92
83	DNMT3A mutations are rare in childhood acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1238-1240.	3.5	34
84	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. <i>Leukemia</i> , 2011, 25, 1365-1368.	7.2	20
85	Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. <i>Leukemia</i> , 2011, 25, 1704-1710.	7.2	73
86	Acetylation of p53 Is Involved in Valproic Acid Induced Death of AML Cells. <i>Blood</i> , 2011, 118, 2461-2461.	1.4	1
87	mTOR Pathway Links Suppressed Autophagy to HDAC Inhibitor-Induced Apoptosis in Myeloid Leukemia. <i>Blood</i> , 2011, 118, 3614-3614.	1.4	1
88	GATA1s Exerts Fetal Stage-Specific Oncogenic Effects in Human Hematopoietic Stem and Progenitor Cells. <i>Blood</i> , 2011, 118, 2355-2355.	1.4	0
89	Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD. <i>Blood</i> , 2011, 118, 3548-3548.	1.4	0
90	Deciphering the Role of Mir-99/125 clusters in the Hematopoietic System. <i>Blood</i> , 2011, 118, 213-213.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. <i>Genes and Development</i> , 2010, 24, 1659-1672.	5.9	122
92	miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. <i>Genes and Development</i> , 2010, 24, 478-490.	5.9	202
93	Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective <i>G-CSF</i> Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 2591-2597.	1.6	62
94	Gene Expression-Based Chemical Genomics Identifies Valproic Acid to Revert the Oncogenic Effect of GATA1s In Down Syndrome Megakaryoblastic Leukemia.. <i>Blood</i> , 2010, 116, 3646-3646.	1.4	0
95	Is Prevention of Myeloid Leukemia Possible?.. <i>Blood</i> , 2009, 114, 481-481.	1.4	1
96	Developmental Stage-Specific Interplay Between GATA1 and IGF Signaling in Fetal Hematopoiesis and Leukemogenesis.. <i>Blood</i> , 2009, 114, 386-386.	1.4	0
97	Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. <i>Blood</i> , 2008, 111, 2991-2998.	1.4	228
98	GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in "Down" Syndrome.. <i>Blood</i> , 2008, 112, 923-923.	1.4	2
99	GATA1s Mutant Protein Contributes to "Down" Syndrome Megakaryoblastic Leukemia by Derepression of E2F Targets.. <i>Blood</i> , 2008, 112, 2248-2248.	1.4	13
100	Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. <i>Leukemia</i> , 2007, 21, 1584-1587.	7.2	30
101	Chromosome 21-Encoded miR-125b and Its Role in the Development of Myeloid Leukemia in Children with Down's Syndrome.. <i>Blood</i> , 2007, 110, 716-716.	1.4	3
102	Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. <i>Haematologica</i> , 2006, 91, 1473-80.	3.5	10
103	Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. <i>Nature Genetics</i> , 2005, 37, 613-619.	21.4	262
104	A Genome-Wide Retroviral Insertional Mutagenesis Screen for Genes Cooperating with Truncated, Oncogenic GATA1s.. <i>Blood</i> , 2005, 106, 2990-2990.	1.4	2
105	Chromosome 21 Encoded RUNX1 and ETS-2 Overexpression in Regenerating Hematopoiesis in Children with Down Syndrome - Implications for Leukemogenesis?.. <i>Blood</i> , 2005, 106, 4373-4373.	1.4	0